CSCR Research Report

Important: All PMIDs below are from training knowledge and must be verified with just fetch-reference PMID:XXXXX before writing any snippet into the YAML. Priority fetch list is at the end.

1. Disease Information

Synonyms: Central serous retinopathy (CSR), CSCR, CSC, central serous chorioretinitis (historical), idiopathic central serous chorioretinopathy.

CSCR is classified by Orphanet as a rare choroidal disorder, but is actually the fourth most common retinal disorder in adults after AMD, diabetic retinopathy, and branch retinal vein occlusion — particularly prevalent in young to middle-aged males.

2. Etiology & Risk Factors

Genetic Risk Factors (GWAS findings)

Key point: CFH and ARMS2/HTRA1 are the same loci associated with AMD — CSCR and AMD share genetic architecture at Bruch membrane/choroidal vascular vulnerability genes.

Environmental Risk Factors

• Corticosteroids (strongest modifiable risk): ~10–40× increased risk; all routes (systemic > intranasal > inhaled > topical skin > epidural). Even brief high-dose burst courses are sufficient. PMID:25654734 (pharmacoepidemiology), PMID:17702499 (review).
• Psychosocial stress / Type A personality: Chronic HPA axis activation → elevated cortisol → MR activation. PMID:15897545.
• Obstructive sleep apnea: OR ~2–4; intermittent hypoxia + cortisol dysregulation. PMID:23736878.
• Pregnancy: Third trimester; elevated placental CRH and cortisol. Usually resolves postpartum. PMID:8778938.
• H. pylori: Multiple case-control studies show association; eradication may help but data conflicting. Controversial.
• Endogenous Cushing syndrome: CSCR can be the presenting feature — check cortisol in severe/bilateral cases.

Mineralocorticoid Receptor Pathway (detailed mechanism)

In choroidal endothelial cells, 11β-HSD2 expression is low, so cortisol is not inactivated locally and freely activates NR3C2 (mineralocorticoid receptor): 1. MR nuclear translocation → upregulates VEGF-A → VEGFR2 phosphorylation of VE-cadherin → junction opening → hyperpermeability 2. Upregulates AQP1 (aquaporin-1) → increased transendothelial water flux 3. Upregulates SERPINE1 (PAI-1) → fibrin deposition in choroid 4. Downregulates tight junction proteins (occludin, claudin-5)

Seminal mechanistic paper: PMID:22446627 (Zhao et al. 2012, J Clin Invest — mineralocorticoid receptor in rat and human chorioretinopathy).

3. Phenotypes (with HPO terms and frequencies)

Note on micropsia: Orphanet explicitly lists micropsia as a CSCR symptom (ORPHA:443079 definition). HPO:HP:0012508 (Metamorphopsia) is the closest; add preferred_term "Micropsia" with a note. Consider also HP:0012508 with a modifier.

Subtype-specific notes: - Acute CSCR: Acute monocular onset; VA often 20/30–20/60; spontaneous improvement expected - Chronic CSCR: Bilateral in ~40%; "descending RPE tracks" (gravity-dependent atrophy); cystoid macular degeneration; subretinal fibrin/precipitates; choroidal neovascularization

4. Genetics / Molecular (detailed)

CFH polymorphisms

• rs800292 (I62V): Risk allele reduces CFH's C3b binding and factor I cofactor activity → less complement regulation at choroidal Bruch membrane → C5a-mediated mast cell degranulation → histamine → permeability increase
• rs1061170 (Y402H): Reduces CFH binding to heparan sulfate in choroid → impaired local complement regulation

Key GWAS papers

1. PMID:25939894 — Schellevis 2015, J Med Genet: First CSCR GWAS (170 cases); CFH rs800292 genome-wide significant (OR 1.59)
2. PMID:29515099 — Schellevis 2018, Ophthalmology: Expanded GWAS (~750 cases); confirmed CFH + new hit ARMS2/HTRA1 (rs10490924, OR 1.38)
3. PMID:31712692 — Hosoda 2020, Japanese GWAS: GATA5 locus; pachychoroid disease spectrum
4. PMID:34385711 — Large European meta-GWAS (>4,200 cases): confirmed CFH, ARMS2/HTRA1; novel hits NR3C2, KCNJ13 (verify this PMID)

NR3C2 variants

GWAS signal is regulatory (non-coding). Rare gain-of-function NR3C2 coding variants reported in familial CSCR cases. Supports constitutive MR hyperactivity as genetic risk mechanism.

KCNJ13

Encodes Kir7.1 inwardly rectifying potassium channel in RPE basolateral membrane. Coding mutations cause Leber congenital amaurosis (monogenic). GWAS variants in CSCR suggest subtler RPE ion transport dysregulation.

No monogenic/Mendelian form established. No CNV/chromosomal abnormalities implicated.

5. Pathophysiology (Detailed Causal Chain)

Node 1: Choroidal Hyperpermeability and Pachychoroid Phenotype

Cell type: CL:0000115 (endothelial cell; preferred_term "choroidal endothelial cell") Biological processes: - GO:0043117 (positive regulation of vascular permeability) — INCREASED - GO:0042921 (glucocorticoid receptor signaling pathway) - GO:0045944 (positive regulation of transcription by RNA polymerase II) — MR-mediated

Pachychoroid structural predisposition: - Dilated outer choroidal vessels (Haller layer "pachyvessels" >200 μm on EDI-OCT) - Compressed inner choroidal layers (Sattler layer, choriocapillaris) - Mean subfoveal choroidal thickness (SFCT) ~450–500 μm in CSCR vs ~280 μm controls

Mechanism: Cortisol → NR3C2 activation → VEGF-A ↑ + AQP1 ↑ + tight junction proteins ↓ → choroidal vascular hyperpermeability. CFH deficiency → complement C3b on choroidal endothelium → C5a → mast cell histamine → amplified permeability.

→ downstream: Retinal Pigment Epithelium Dysfunction

Node 2: Retinal Pigment Epithelium Dysfunction

Cell type: CL:0002586 (retinal pigment epithelial cell) Biological processes: - GO:0006811 (monoatomic ion transport) — DECREASED (Na⁺/K⁺-ATPase failure) - GO:0070588 (calcium ion transmembrane transport) — disrupted - GO:0045087 (innate immune response) — complement deposition on RPE basal surface

Key events: - Hydrostatic pressure from hyperpermeant choriocapillaris → RPE tight junction disruption (occludin, ZO-1, claudin-19 ↓) - Focal RPE detachments → serous pigment epithelial detachments (PEDs) - SERPINE1 (PAI-1) upregulation → fibrin deposition in sub-RPE space - Chronic: diffuse RPE atrophy, "descending tracks" on FA

→ downstream: Subretinal Fluid Accumulation and Macular Detachment

Node 3: Subretinal Fluid Accumulation and Photoreceptor Damage

Cell types: - CL:0000210 (photoreceptor cell) - CL:0000573 (retinal cone cell) — most metabolically vulnerable; foveal cones first affected - CL:0000604 (retinal rod cell) — impaired dark adaptation in chronic

Biological processes: - GO:0007601 (visual perception) — DECREASED - GO:0007602 (phototransduction) — DECREASED - GO:0006915 (apoptotic process) — INCREASED in chronic disease (photoreceptor death) - GO:0001525 (angiogenesis) — INCREASED in CNV complication

Key events: - Neurosensory retinal detachment → photoreceptor outer segment disruption - Ellipsoid zone (EZ) disruption on OCT = marker of photoreceptor outer segment integrity loss - Outer nuclear layer (ONL) thinning on OCT = photoreceptor cell body loss - In acute: reversible upon SRF resolution - In chronic: irreversible photoreceptor loss, permanent VA reduction

Node 4 (Complication): Choroidal Neovascularization

• Chronic RPE atrophy + Bruch membrane damage → VEGF-A ↑ → angiogenesis
• Type 1 (sub-RPE) CNV develops in ~5–10% chronic CSCR over 5 years
• Evolution to pachychoroid neovasculopathy spectrum

6. Diagnostics

OCT (primary diagnostic tool)

• Subfoveal fluid (SRF): hyporeflective space under neurosensory retina
• Pigment epithelial detachments (PEDs): dome-shaped RPE elevation
• Ellipsoid zone (EZ) disruption: photoreceptor outer segment loss
• Outer nuclear layer (ONL) thinning: photoreceptor cell loss
• SFCT measurement: >300–350 μm indicates pachychoroid

Fluorescein Angiography (FA)

• "Smoke-stack" pattern (~10–20%): single leakage point with upward mushroom-cloud expansion
• "Ink-blot" pattern (~80%): gradually expanding spot of hyperfluorescence
• "Descending RPE tracks" in chronic: gravity-dependent RPE decompensation

Indocyanine Green Angiography (ICGA)

• Early: choroidal hyperpermeability zones
• Late: persistent hyperfluorescence of dilated pachyvessels
• Essential for: treatment planning (PDT spot targeting), distinguishing CNV from pure CSCR

OCT-Angiography (OCT-A)

• Choriocapillaris flow deficits under SRF area
• CNV detection (type 1 sub-RPE flow signal)
• No dye required

Enhanced Depth Imaging OCT (EDI-OCT)

• Visualizes pachyvessels (Haller layer dilated veins >200 μm)
• Measures SFCT

Multifocal ERG

• Reduced central P1 amplitude; prolonged implicit time
• Quantifies functional macular loss beyond Snellen acuity

Cortisol markers (in selected cases)

• 24-hour urinary free cortisol, salivary late-night cortisol: if Cushing syndrome suspected
• Not routine for typical CSCR

7. Epidemiology

• Incidence: 9.9/100,000/year in men, 1.7/100,000/year in women (PMID:24974790, Olmsted County, MN population-based study)
• Male:female ratio: ~6:1 overall (acute); narrows to ~3:1 in chronic/older presentations
• Peak age: 30–50 years; females present ~5–10 years later than males
• Bilateral: Typically unilateral at presentation; ~40% develop fellow-eye involvement over lifetime
• Recurrence: ~40–50% recur within 1 year after spontaneous resolution
• Ethnic variation: Higher incidence in Asian (East Asian, South Asian), Hispanic, Middle Eastern populations vs Northern European
• Inheritance: Complex/multifactorial; not Mendelian. Rare familial clustering (shared NR3C2 or CFH variants)

8. Temporal Development

• Residual symptoms (contrast, metamorphopsia) persist in ~30% even after SRF resolution in acute
• Long-term: BCVA 20/40 or worse at 5 years in ~20–30% chronic untreated (PMID:19683830)
• CNV develops in ~5–10% chronic over 5 years

9. Treatment (comprehensive)

Observation / Supportive Care

• MAXO:0000950 (supportive care)
• First-line in acute CSCR; most resolve in <3 months
• Discontinue corticosteroids; treat OSA; stress management
• Monthly OCT monitoring; intervene if no resolution by 3–4 months

Half-Dose Photodynamic Therapy with Verteporfin — Standard of Care for Chronic CSCR

• NCIT:C15300 (Photodynamic Therapy)
• CHEBI:32293 (verteporfin)
• Mechanism: Verteporfin accumulates in abnormal choroidal pachyvessels → 689 nm laser activation → singlet oxygen → endothelial damage → thrombosis → normalized choroidal blood flow and permeability
• Half-dose protocol: 3 mg/m² BSA (vs standard 6 mg/m²) minimizes RPE damage
• PLACE trial (PMID:29229468): RCT half-dose PDT vs micropulse laser; 67% complete SRF resolution with PDT vs 29% micropulse at 7 weeks — definitive evidence for PDT superiority
• Earlier RCT evidence: PMID:15232060 (Chan 2008 — first PDT RCT for CSCR)
• ICGA-guided treatment targeting choroidal hyperpermeability zones (not just FA leakage point)

Mineralocorticoid Receptor Antagonists

• NCIT:C15986 (Pharmacotherapy)
• Eplerenone: CHEBI:31547 — selective MR antagonist
• Spironolactone: CHEBI:9241 — non-selective MR antagonist
• VICI trial (PMID:32014115): Definitive RCT (Lotery 2020, Lancet): eplerenone NOT significantly effective vs placebo in chronic CSCR (SRF reduction −19.7 μm vs −7.6 μm placebo; p=0.18). This is a largely negative trial — critical for accuracy.
• Spironolactone: small RCTs/open-label series suggest possible benefit (PMID:23539526) but no definitive large RCT
• Ongoing debate: continue off-label use in selected patients (high cortisol, cortisol-driven cases)
• Uncertainty flag: VICI negative result does not rule out benefit in specific subgroups; higher-selectivity agents (finerenone) under investigation

Focal Laser Photocoagulation

• NCIT:C62730 (Infrared Photocoagulation Therapy)
• For extrafoveal leakage points only; creates permanent scotoma at treatment site
• Accelerates resolution in acute extrafoveal disease; NOT for subfoveal/juxtafoveal leaks
• Less used since PDT demonstrated superior safety/efficacy

Anti-VEGF Therapy (for CNV complication only)

• NOT first-line for uncomplicated CSCR — MR-driven mechanism not primarily VEGF
• Standard of care for type 1 or type 2 CNV complicating chronic CSCR
• Agents: bevacizumab (NCIT:C2038), ranibizumab (NCIT:C48135), aflibercept (NCIT:C64468)

Micropulse Subthreshold Laser

• 577 nm or 810 nm; no visible burn; RPE stimulation without destruction
• Inferior to half-dose PDT in PLACE trial (29% vs 67% SRF resolution)
• Used when PDT unavailable or contraindicated; avoids scotoma risk of conventional laser

Oral Rifampicin

• CHEBI:28077 (rifampicin)
• Mechanism: CYP3A4/CYP2C8/CYP2C9 inducer → accelerates cortisol catabolism → reduces systemic cortisol → reduces choroidal MR activation
• PMID:25138772 (Shulman 2014 — open-label series); small benefit shown
• Limited by significant drug–drug interactions and hepatotoxicity risk

Mifepristone (Glucocorticoid Receptor Antagonist)

• CHEBI:50692 (mifepristone)
• GR (NR3C1) antagonist; blocks glucocorticoid signaling in choroid
• Small RCT evidence of benefit in recurrent CSCR (PMID:20142386)
• Limited by antiprogestational effects

Finasteride (Androgen Hypothesis)

• CHEBI:5100 (finasteride) — 5α-reductase inhibitor
• Rationale: CSCR male-predominance may reflect androgen-mediated choroidal vasoreactivity
• PMID:19325499 (Haimovici — pilot data); very limited evidence. Uncertainty flag.

10. Prevention

Primary: - Avoid/minimize corticosteroids; use lowest effective dose, shortest duration, prefer non-systemic routes where possible - Ophthalmology monitoring if corticosteroids medically necessary - Stress management; treat OSA - No genetic screening recommended

Secondary (preventing progression/recurrence): - Monthly OCT during active phase; 3-monthly in remission - Screen for endogenous Cushing syndrome in severe/bilateral cases - Patient education on recurrence triggers (steroids, stress, sleep deprivation) - Monitor fellow eye — 40% cumulative bilateral involvement

11. Prognosis

Quality of life significantly impaired even with "normal" Snellen acuity — contrast sensitivity, color discrimination, metamorphopsia, reading difficulty are common residual complaints (PMID:28122842).

12. Animal Models

HUMAN_MODEL_MISMATCH: Rodent models cannot replicate the pachychoroid structural predisposition or the human-specific CFH/ARMS2 genetic architecture. MR pharmacology insights are translatable, but full CSCR pathophysiology is not modeled in rodents. PMID:22446627 provides mechanistic data (murine), but its translational validity to human pachychoroid disease requires caution.

13. Ontology Term Reference Summary

Cell Types (CL)

• CL:0000115 — endothelial cell (use preferred_term: "choroidal endothelial cell")
• CL:0002586 — retinal pigment epithelial cell
• CL:0000210 — photoreceptor cell
• CL:0000573 — retinal cone cell
• CL:0000604 — retinal rod cell

Biological Processes (GO)

• GO:0043117 — positive regulation of vascular permeability (INCREASED in choroid)
• GO:0006811 — monoatomic ion transport (DECREASED in RPE)
• GO:0007601 — visual perception (DECREASED)
• GO:0007602 — phototransduction (DECREASED)
• GO:0001525 — angiogenesis (INCREASED in CNV complication)
• GO:0006915 — apoptotic process (INCREASED in chronic photoreceptor loss)
• GO:0042921 — glucocorticoid receptor signaling pathway
• GO:0045944 — positive regulation of transcription by RNA polymerase II (MR-mediated)

Anatomical Structures (UBERON)

• UBERON:0001777 — choroid
• UBERON:0002320 — retinal pigment epithelium
• UBERON:0003384 — photoreceptor layer of retina
• UBERON:0001629 — outer nuclear layer of retina
• UBERON:0003386 — macula lutea
• UBERON:0004904 — Bruch's membrane (verify UBERON ID)

Treatments

• MAXO:0000950 — supportive care
• NCIT:C15300 — Photodynamic Therapy
• NCIT:C15986 — Pharmacotherapy
• NCIT:C62730 — Infrared Photocoagulation Therapy

Drugs (CHEBI)

• CHEBI:32293 — verteporfin
• CHEBI:31547 — eplerenone
• CHEBI:9241 — spironolactone
• CHEBI:28077 — rifampicin
• CHEBI:50692 — mifepristone
• CHEBI:5100 — finasteride

14. Priority PMIDs to Fetch

Run these immediately before adding evidence to the YAML:

just fetch-reference PMID:22446627   # Zhao 2012 J Clin Invest — seminal MR mechanism paper
just fetch-reference PMID:29229468   # van Dijk 2018 Ophthalmology — PLACE trial (PDT vs micropulse)
just fetch-reference PMID:32014115   # Lotery 2020 Lancet — VICI trial (eplerenone, NEGATIVE result)
just fetch-reference PMID:25939894   # Schellevis 2015 J Med Genet — first CSCR GWAS (CFH)
just fetch-reference PMID:29515099   # Schellevis 2018 Ophthalmology — second GWAS (ARMS2/HTRA1)
just fetch-reference PMID:24974790   # Kitzmann 2008 Ophthalmology — epidemiology/incidence
just fetch-reference PMID:28122842   # van Rijssen 2019 Prog Retin Eye Res — treatment review
just fetch-reference PMID:17702499   # Bouzas 2002 Surv Ophthalmol — corticosteroid association
just fetch-reference PMID:23380442   # Gemenetzi 2010 Eye — pathogenesis review
just fetch-reference PMID:25654734   # Tsai 2015 Retina — corticosteroid pharmacoepidemiology
just fetch-reference PMID:23736878   # Li 2013 — OSA association
just fetch-reference PMID:31712692   # Hosoda 2020 — GATA5 Japanese GWAS
just fetch-reference PMID:23539526   # Bousquet — spironolactone RCT
just fetch-reference PMID:15232060   # Chan 2008 — first PDT RCT for CSCR
just fetch-reference PMID:19683830   # Loo — long-term VA outcomes

15. Key Active Debates / Uncertainties

1. VICI trial interpretation: Eplerenone failed but MR mechanism is well-established. Ongoing: Is a more selective MR antagonist (finerenone) effective? Was dosing/patient selection suboptimal?
2. Pachychoroid: predisposition vs. acquired phenotype? Most evidence favors it as a primary genetic vascular anatomy trait.
3. ARMS2/HTRA1 mechanism in CSCR: Why does this AMD locus confer CSCR risk? Likely shared Bruch membrane/choroidal vulnerability but specific mechanism unknown.
4. H. pylori association: Causal link not established; possibly confounded by socioeconomic factors.
5. Anti-VEGF in uncomplicated CSCR: Current consensus is reserve for CNV only; multiple negative small RCTs for primary CSCR.
6. Androgen hypothesis: Male predominance not fully explained by corticosteroid/stress exposure alone; finasteride data insufficient.
7. HUMAN_MODEL_MISMATCH: Rodent MR models cannot recapitulate human pachychoroid anatomy; translate pharmacology insights cautiously.

This report adds substantial depth to the existing stub — notably: the GWAS genetics section (CFH, ARMS2/HTRA1, NR3C2, GATA5, KCNJ13), the detailed MR molecular mechanism, the pachychoroid phenotype concept, expanded phenotypes (adding micropsia, dyschromatopsia, nyctalopia, ERG findings), the VICI trial negative result for eplerenone (critical for accuracy), the PLACE trial data establishing PDT as standard of care, and the animal model HUMAN_MODEL_MISMATCH flag. Use just fetch-reference PMID:XXXXX for each PMID before writing snippets into YAML.